ESMO 2025 – Padcev plus Keytruda sets the perioperative bar
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
Astra pulls further ahead of Merck’s Curon project
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
ESMO 2025 preview – Astra and Daiichi keep abreast of Gilead
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
